9WV.F NUTRIBAND INC. DL -001
- Market cap
- EUR 63.2M
- P/E
- -
- P/B
- 12.76x
- ROE
- -79.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jul 2026.
Is 9WV.F undervalued?
Graham numberThe Graham number of NUTRIBAND INC. DL -001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NUTRIBAND INC. DL -001 fundamental analysis
No fundamental analysis for NUTRIBAND INC. DL -001 yet.
NUTRIBAND INC. DL -001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NUTRIBAND INC. DL -001
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Full company profileNUTRIBAND INC. DL -001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jul 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NUTRIBAND INC. DL -001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 1.42M | 2.08M | 2.09M | 2.14M | 2.04M | 1.74M |
| Gross Profit | 504K | 750K | 862K | 743K | 566K | 757K |
| Operating Income | -3.93M | -4.15M | -4.87M | -6.69M | -8.32M | -4.29M |
| EBITDA | - | -4.15M | -5.12M | -10.2M | -8.01M | -4.09M |
| Net Income | -6.18M | -4.48M | -5.49M | -10.5M | -8.23M | -4.25M |
| EPS | -0.67 | -0.57 | -0.62 | -0.95 | -0.68 | -0.35 |
| Balance Sheet | ||||||
| Total Assets | 12.7M | 9.46M | 7.52M | 7.47M | 7.55M | 6.29M |
| Total Liabilities | 880K | 883K | 1.08M | 1.04M | 868K | 964K |
| Shareholders' Equity | 11.9M | 8.57M | 6.44M | 6.43M | 6.68M | 5.33M |
| Cash & Short-term Investments | 4.89M | 1.99M | 493K | 4.31M | 4.57M | 3.42M |
| Cash Flow | ||||||
| Operating Cash Flow | -2.81M | -2.99M | -3.53M | -4.63M | -5.13M | -2.30M |
| Capital Expenditure | 81.6K | 79.3K | 51.8K | 92.0K | 5.32K | 0.00 |
| Free Cash Flow | -2.89M | -3.07M | -3.58M | -4.72M | -5.14M | -2.30M |
| Ratios | ||||||
| ROE | -52.1% | -52.3% | -85.2% | -163.1% | -123.2% | -79.7% |
| ROA | -48.5% | -47.4% | -73.0% | -140.3% | -109.0% | -67.5% |
| Net Profit Margin | -434.3% | -215.6% | -263.0% | -489.9% | -404.1% | -243.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NUTRIBAND INC. DL -001 dividends
NUTRIBAND INC. DL -001 has not paid dividends in the last 5 fiscal years.
Last stock split: 7:6 on Aug 12, 2022.
Who owns NUTRIBAND INC. DL -001
- Insiders 59.09%
- Institutions 3.24%
- Public & others 37.67%
- Shares outstanding 12.2M
- Free float 5.28M
NUTRIBAND INC. DL -001 company profile
- Company name
- NUTRIBAND INC. DL -001
- Ticker
- 9WV.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- January
- Address
- 121 South Orange Avenue, Orlando, FL, United States, 32801
- Phone
- 407 377 6695
- Website
- nutriband.com
About NUTRIBAND INC. DL -001
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
NUTRIBAND INC. DL -001 management
7- Mr. Serguei MelnikFounder, President, Company Secretary & Executive Chairman · born 1974
- Mr. Gareth SheridanFounder, CEO & Director · born 1990
- Mr. Gerald GoodmanCFO & Chief Accounting Officer · born 1948
- Dr. Alan Smith Ph.D.COO & President of 4P Therapeutics · born 1966
- Dr. Jeffrey Patrick Pharm.D.Chief Scientific Officer · born 1970
- Mr. Michael MyerPresident of Pocono Pharmaceutical · born 1984
- Mr. Tyler OverkHead of Active Intelligence · born 1984